Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eylea bests Lucentis in DME, but Avastin wins on cost

This article was originally published in Scrip

Executive Summary

An investigator-sponsored clinical trial found that three vascular endothelial growth factor (VEGF) inhibitors work similarly well in about 75% of diabetic macular edema (DME), while Eylea (aflibercept) from Regeneron Pharmaceuticals outperformed Genentech's Lucentis (ranibizumab) and Avastin (bevacizumab) in the 25% of DME patients with more severe vision loss, but a separate physician opinion recommends off-label Avastin for most patients due to its much lower cost.


Related Content

Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts